Related Experiment Video
Updated: Nov 24, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Novel therapeutic compounds for prostate adenocarcinoma treatment: An analysis using bioinformatic approaches and the
Kai Li1, Jingyuan Fan1, Xinyi Qin2
1Departments of Orthopedics, The First Affiliated Hospital, Guangxi Medical University.
Introduction:
Prostate adenocarcinoma is the most frequently diagnosed malignancy, particularly for people >70 years old. The main challenge in the treatment of advanced neoplasm is bone metastasis and therapeutic resistance for known oncology drugs. Novel treatment methods to prolong the survival time and improve the life quality of these specific patients are required. The present study attempted to screen potential therapeutic compounds for the tumor through bioinformatics approaches, in order to provide conceptual treatment for this malignant disease.
Methods:
Differentially expressed genes were obtained from the Gene Expression Omnibus database and submitted into the Connectivity Map database for the detection of potentially associated compounds. Target genes were extracted from the search results. Functional annotation and pathway enrichment were performed for the confirmation. Survival analysis was used to measure potential therapeutic effects.
Results:
It was revealed that 3 compounds (vanoxerine, tolnaftate, and gabexate) may help to prolong the disease-free survival time from tumor metastasis of patients with the tumor. A total of 6 genes [also-keto reductase family 1 member C3 (AKR1C3), collagen type III α 1 chain (COL3A1), lipoprotein lipase (LPL), glucuronidase, β pseudogene 11 (GUSBP11), apolipoprotein E (APOE), and collagen type I α 1 chain (COL1A1)] were identified to be the potential therapeutic targets for the aforementioned compounds.
Conclusion:
In the present study, it was speculated that 3 compounds may function as the potential therapeutic drugs of bone metastatic prostate adenocarcinoma; however, further studies verifying vitro and in vivo are necessary.
Insights
This study identified three compounds: vanoxerine, tolnaftate, and gabexate, as potential treatments for bone metastatic prostate adenocarcinoma. These compounds may help prolong disease-free survival by targeting specific genes involved in tumor progression.
Area of Science:
- Oncology
- Bioinformatics
- Pharmacology
Background:
- Prostate adenocarcinoma is a prevalent malignancy, especially in older adults.
- Bone metastasis and drug resistance pose significant challenges in advanced prostate cancer treatment.
- Novel therapeutic strategies are needed to improve survival and quality of life.
Purpose of the Study:
- To screen for potential therapeutic compounds for prostate adenocarcinoma using bioinformatics.
- To identify novel treatment concepts for advanced prostate cancer with bone metastasis.
Main Methods:
- Utilized Gene Expression Omnibus and Connectivity Map databases to identify compounds associated with differentially expressed genes.
- Performed functional annotation, pathway enrichment, and survival analysis.
- Extracted target genes for identified compounds.
Main Results:
- Identified vanoxerine, tolnaftate, and gabexate as potential compounds to prolong disease-free survival.
- Pinpointed six key genes (AKR1C3, COL3A1, LPL, GUSBP11, APOE, COL1A1) as therapeutic targets.
- These genes are implicated in the mechanism of action for the identified compounds.
Conclusions:
- Vanoxerine, tolnaftate, and gabexate are proposed as potential therapeutic agents for bone metastatic prostate adenocarcinoma.
- Further in vitro and in vivo studies are required to validate these findings.
- The identified genes represent potential targets for future drug development.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...